Friday , December 3 2021

Tilray® signs global collaboration with leading pharmaceutical companies



[ad_1]

NANAIMO, British Columbia – (BUSINESS WIRE) – Tilray Canada Ltd., a subsidiary of Tilray Inc. (NASDAQ: TLRY), a global
pioneering in the production, research and distribution of medical
cannabis, announced today that it was a global framework
agreement ("framework agreement") to cooperate with Sandoz AG, a
global leader in generic drugs and biosimilarer and part of
Novartis Group, to increase access to high-quality medical
cannabis products worldwide.

A development of an existing alliance between Tilray and Sandoz Canada,
The framework agreement represents the two companies' intentions
to act jointly in jurisdictions where cannabis is or will be
approved for medical purposes.

Tilray, a global pioneer in medical cannabis, has products available in
twelve countries and operations in Australia and New Zealand, Canada,
Germany, Latin America and Portugal. The agreement is based on Tilray's
groundbreaking track record that a company is committed to making
pharmaceutical cannabis products of pharmaceutical grade available to patients
In need. Tilray was the first licensed medical cannabis producer in
North America to get current Good Manufacturing Practice (cGMP)
certification in accordance with the European Medicines Agency (EMA)
standards.

"This agreement represents an important milestone in the movement to provide
Access to safe, GMP-certified medical cannabis for patients in need
worldwide, "says Brendan Kennedy, Chief Executive Officer Tilray.
"Tilray is a global company and we are proud to build on our success
and momentum from our existing deal with Sandoz Canada by taking
our partnership globally. Sandoz AG will be a valuable partner when we work
together to improve access to high quality medical cannabis
products in countries around the world. "

The framework agreement describes the opportunities for companies to
agrees to cooperate in various forms:

  • Sandoz AG can support the global commercialization of Tilray's
    non-smokeless / non-combustible medical cannabis products;

  • Tilray and Sandoz AG may brand certain non-smokeless / non-combustible
    Products;

  • Tilray can deliver non-smokable / non-combustible medical cannabis
    products and license rights to and from Sandoz AG in relation to such
    Products; Both companies can also work together to make use of the best in the class
    knowledge to educate pharmacists and doctors about medical cannabis
    Products;

  • Tilray and Sandoz AG can collaborate to develop new innovative medical
    cannabis products.

About Tilray®

Tilray is
a global pioneer in research, cultivation, production and
distribution of cannabis and cannabinoids currently serving dozens
of thousands of patients in twelve countries spanning five continents.

This press release contains "forward looking statements" within
the meaning of the American case law case law case law of 1995 and
"Forward-looking information" within the meaning of Canadian securities
laws or collective forward looking statements. farsighted
Statements in this press release can be identified by words
like "may", "would", "could", "will", "likely", "expect"
"Foresee", "believe" refers to "," plan "," forecast "," project "
"Estimate", "outlook" and other similar expressions and include
statements concerning the global success of Tilray and Sandoz AG
cooperation. Forward-looking statements are not a guarantee of the future
performance and based on a number of estimates and assumptions of
leadership in the light of management's experience and perception of trends,
current conditions and expected development as well as other factors
that management considers it relevant and reasonable in
circumstances, including assumptions about current and future
market conditions, current and future legislation and
future approvals and permits. Actual results, performance or performance
may differ materially from what is expressed in or implied by someone
forward-looking statements in this press release, and thus you
should not place undue dependence on such prospects
and they are not guarantees for future results. farsighted
statements imply significant risks, assumptions, uncertainties and
Other factors that can cause actual future results or expected events
to differ materially from the expressed or implied of someone
Forward looking statements. See the heading "Risk Factors" in
Tilray quarterly report on Form 10-Q, filed with
Securities and Exchange Commission and Canadian Securities Regulators
November 14, 2018, for a discussion of the essential risk factors such as
can get actual results to differ significantly from forward looking
information. Tilray does not undertake to update any forward looking
statements included here except in accordance with
current securities legislation.

[ad_2]
Source link